Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Hammer

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Experimental Medicine|March 1, 1982
Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial deathK A Joiner, C H Hammer, E J Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1982
The use of conglutinin in a quantitative assay for the presence of cell-bound C3bi and evidence that a single molecule of C3bi is capable of binding conglutininE J Brown, T A Gaither, C H Hammer, et al.
The Journal of Clinical Investigation|January 1, 1982
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremiaE J Brown, S W Hosea, C H Hammer, et al.
Journal of Immunological Methods|December 27, 1985
Quantitation of activation of the human terminal complement pathway by ELISAM E Sanders, M A Schmetz, C H Hammer, et al.
The Journal of Investigative Dermatology|August 1, 1989
Generation of C5-dependent bioactivity by tissue-bound anti-BMZ autoantibodiesW R Gammon, K B Yancey, K L Mangum, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement systemE J Brown, K A Joiner, T A Gaither, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1983
Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristicsC L Koski, L E Ramm, C H Hammer, et al.
Molecular Immunology|June 1, 1983
Cleavage of membrane-bound C3b and C3bi by viable human neutrophils (PMN)T A Gaither, C H Hammer, J E Gadek, et al.
The Journal of Clinical Investigation|February 1, 1985
Studies of human C5a as a mediator of inflammation in normal human skinK B Yancey, C H Hammer, L Harvath, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1990
Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9S M Puentes, R P Da Silva, D L Sacks, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Experimental Medicine|March 1, 1982
Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial deathK A Joiner, C H Hammer, E J Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1982
The use of conglutinin in a quantitative assay for the presence of cell-bound C3bi and evidence that a single molecule of C3bi is capable of binding conglutininE J Brown, T A Gaither, C H Hammer, et al.
The Journal of Clinical Investigation|January 1, 1982
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremiaE J Brown, S W Hosea, C H Hammer, et al.
Journal of Immunological Methods|December 27, 1985
Quantitation of activation of the human terminal complement pathway by ELISAM E Sanders, M A Schmetz, C H Hammer, et al.
The Journal of Investigative Dermatology|August 1, 1989
Generation of C5-dependent bioactivity by tissue-bound anti-BMZ autoantibodiesW R Gammon, K B Yancey, K L Mangum, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement systemE J Brown, K A Joiner, T A Gaither, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1983
Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristicsC L Koski, L E Ramm, C H Hammer, et al.
Molecular Immunology|June 1, 1983
Cleavage of membrane-bound C3b and C3bi by viable human neutrophils (PMN)T A Gaither, C H Hammer, J E Gadek, et al.
The Journal of Clinical Investigation|February 1, 1985
Studies of human C5a as a mediator of inflammation in normal human skinK B Yancey, C H Hammer, L Harvath, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1990
Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9S M Puentes, R P Da Silva, D L Sacks, et al.
Pageof 7